Humacyte reports ATEV shows low atherosclerosis risk in long term results

Humacyte reports ATEV shows low atherosclerosis risk in long term results
Humacyte reveals ATEV trial results

Humacyte presented new long term clinical data for its ATEV vessel at the 2026 ISVTE-ISACB Joint Meeting in Miami.

The analysis covered ATEVs from 52 patients enrolled across five clinical trials, providing important insight into the vessel's low susceptibility to atherosclerosis over time.

Humacyte previously presented interim Phase 3 results for its ATEV vessel in women requiring hemodialysis access at Kidney Week. The company has also shared new clinical data on its bioengineered human vessels at VEITHsymposium. These earlier updates focused on advances in tissue engineered vascular grafts.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.